Trial · NCT02110264

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)

NCT02110264, Phase 3, Completed, University of California, Los Angeles; results first posted 2020-01-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Injectable Pharmacotherapy for Opioid Use Disorders (IPOD). Trials, record NCT02110264. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02110264

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
NCT number: NCT02110264
Status: Completed
Phases: Phase 3
Enrollment: 151 participants, actual
Lead sponsor: University of California, Los Angeles
Conditions: Opioid Use Disorders
Interventions: XR-NTX, XR-NTX+PN, ETAU
First posted: 2014-04-10
Last updated: 2020-01-22
Results first posted: 2020-01-22

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Opioid Use	6 months	The primary objective is to compare outcomes of the three intervention groups, based on self-reports at 6-months post-intervention.
Secondary	Opioid Use Disorder	6 months	Number of participants meeting DSM-5 OUD (opioid use disorder) criteria via modified CIDI-2 Substance Abuse Module

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Opioid Use	6 months		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Opioid Use Disorder	6 months		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Opioid Use	Vivitrol (XR-NTX)	6	Participants
Opioid Use	XR-NTX+PN	12	Participants
Opioid Use	ETAU	7	Participants
Opioid Use Disorder	Vivitrol (XR-NTX)	4	Participants
Opioid Use Disorder	XR-NTX+PN	4	Participants
Opioid Use Disorder	ETAU	3	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Vivitrol (XR-NTX)	53
Overall Study	STARTED	XR-NTX+PN	50
Overall Study	STARTED	ETAU	48
Overall Study	COMPLETED	Vivitrol (XR-NTX)	35
Overall Study	COMPLETED	XR-NTX+PN	38
Overall Study	COMPLETED	ETAU	39
Overall Study	NOT COMPLETED	Vivitrol (XR-NTX)	18
Overall Study	NOT COMPLETED	XR-NTX+PN	12
Overall Study	NOT COMPLETED	ETAU	9

Source ClinicalTrials.gov

Adverse events15

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Pain at injection site	General disorders	Vivitrol (XR-NTX)	2	53
other	Pain at injection site	General disorders	XR-NTX+PN	4	50
other	Pain at injection site	General disorders	ETAU	0	48
other	Precipitated withdrawal	Injury, poisoning and procedural complications	Vivitrol (XR-NTX)	1	53
other	Precipitated withdrawal	Injury, poisoning and procedural complications	XR-NTX+PN	1	50
other	Precipitated withdrawal	Injury, poisoning and procedural complications	ETAU	0	48
other	photophobia	Eye disorders	Vivitrol (XR-NTX)	1	53
other	photophobia	Eye disorders	XR-NTX+PN	0	50
other	photophobia	Eye disorders	ETAU	0	48
other	Blurred vision	Eye disorders	Vivitrol (XR-NTX)	1	53

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Vivitrol (XR-NTX)	0	53
Total, all-cause mortality	XR-NTX+PN	0	50
Total, all-cause mortality	ETAU	0	48
Total, other adverse events	Vivitrol (XR-NTX)	4	53
Total, other adverse events	XR-NTX+PN	5	50
Total, other adverse events	ETAU	0	48
Total, serious adverse events	Vivitrol (XR-NTX)	0	53
Total, serious adverse events	XR-NTX+PN	1	50
Total, serious adverse events	ETAU	0	48

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
27282118	DERIVED	PubMed
40342086	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02110264

GET https://conductscience.org/api/trials/v1/NCT02110264/registered

API reference For AI assistants